@prefix dcterms: . @prefix ns1: . @prefix this: . @prefix sub: . @prefix np: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix nkg: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression."; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:has_population_context sub:cohort; bl:provided_by ; bl:publications ; bl:relation nkg:OffLabelIndication . sub:cohort rdfs:label "Adults"; bl:category bl:Cohort . bl:category bl:Drug . } sub:provenance { sub:assertion ns1:wasAttributedTo orcid:0000-0002-7641-6446 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB"; npx:hasSignature "F/QVLTETAI1pgSMF2NG1OAXz4hjTOPwEU0P/CRD/qRx/CPwZglDAyJnIid50o1EStU+F0JojVFHbKxFTU3kIFil57/NFukXjPmG9QI8Nb/86OB6kIlwxF3hNJlzCSuZzVmukraVQWgEWAUjK+ZyKjE7yTPbg+ZJ1mfo46x6kCK8="; npx:hasSignatureTarget this: . this: dcterms:created "2021-06-28T20:03:25.830+02:00"^^xsd:dateTime; dcterms:creator orcid:0000-0002-7641-6446; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }